Deramiocel (CAP-1002) is an investigational allogeneic cardiac-derived cell therapy in late-stage development for Duchenne muscular dystrophy cardiomyopathy. Capricor reports resumed FDA BLA review with a PDUFA action date in August 2026. The therapy is intended to address both cardiac and skeletal disease manifestations through immunomodulatory and anti-fibrotic effects.
Diamyd Medical anticipates March 2026 interim results from its Phase 3 diabetes trial that could support a BLA pathway. Capricor Therapeutics awaits an August 2026 FDA decision on its Duchenne muscular dystrophy treatment BLA. Bicara Therapeutics prepares for Phase 3 study initiation of its oncology candidate toward future BLA submission.
The FDA has lifted a Complete Response Letter and resumed review of Capricor Therapeutics' Biologics License Application for deramiocel, setting a PDUFA date of August 22nd. The company ended 2025 with $318M in cash.
PTC Therapeutics withdrew its resubmitted new drug application for Translarna in Duchenne muscular dystrophy after the FDA indicated the data was unlikely to meet the threshold for substantial evidence of effectiveness, marking the third unsuccessful US approval attempt.
